Developing a vaccine for human immunodeficiency virus (HIV) may be aided by a complete understanding of those rare cases in which some HIV-infected individuals control replication of the virus [1] [2] [3] . Most of these elite controllers express the histocompatibility alleles HLA-B*57 or HLA-B*27 (ref. 3) . These alleles remain by far the most robust associations with low concentrations of plasma virus 4, 5 , yet the mechanism of control in these individuals is not entirely clear. Here we vaccinate Indian rhesus macaques that express Mamu-B*08, an animal model for HLA-B*27-mediated elite control 6 , with three Mamu-B*08-restricted CD8
1 T-cell epitopes, and demonstrate that these vaccinated animals control replication of the highly pathogenic clonal simian immunodeficiency virus (SIV) mac239 virus. High frequencies of CD8 1 T cells against these Vif and Nef epitopes in the blood, lymph nodes and colon were associated with viral control. Moreover, the frequency of the CD8 1 T-cell response against the Nef RL10 epitope (Nef amino acids 137-146) correlated significantly with reduced acute phase viraemia. Finally, two of the eight vaccinees lost control of viral replication in the chronic phase, concomitant with escape in all three targeted epitopes, further implicating these three CD8
1 T-cell responses in the control of viral replication. Our findings indicate that narrowly targeted vaccine-induced virus-specific CD8
1 T-cell responses can control replication of the AIDS virus.
A vaccine is desperately needed to curb the global HIV pandemic. Estimates project that for every HIV-infected individual initiating antiretroviral treatment, more than two individuals are newly infected 7 . Vaccines have historically been chosen based on their ability to induce responses that mimic successful immune responses to human pathogens, yet correlates of successful immune responses against HIV remain an enigma. Elite control of chronic phase viral replication is the best example of an effective immune response against the virus 1 . Understanding why elite controllers control viral replication may enable the design of an effective vaccine for HIV.
Recently, we have discovered similarities between an animal model of elite control and the same phenomenon in humans 8 . The Indian rhesus macaque major histocompatibility complex (MHC) class I molecule Mamu-B*08 and the human leukocyte antigen (HLA) class I molecule HLA-B*27 bind many of the same peptides 6 . Despite being divergent at 28 amino acid positions, these molecules share similar peptide-binding motifs, including an identical position 2 arginine primary anchor 6 . Both MHC class I molecules also exhibit considerable overlap in preferred binding residues at the other dominant position 1 and position 9 residues 6 . Remarkably, 50% of Mamu-B*08 1 animals show some measure of control of the highly pathogenic SIVmac239 virus 6, 9 . It is important to note, however, that several key differences exist between HLA-B*27-mediated elite control and the Mamu-B*08 1 animal model. Humans are infected with a variety of different viruses and it is widely thought that CD8
1 T cells directed against conserved epitopes in Gag have an important role in viral control 1 . By contrast, the animal model of elite control has been developed using macaques infected only with the SIVmac239 clone. Furthermore, Mamu-B*08
1 macaques do not usually recognize Gagderived epitopes 10 . Finally, Indian rhesus macaques infected with SIVmac239 have average chronic phase viral loads of more than 10 6 viral RNA (vRNA) copies per millilitre, whereas humans normally have mean plasma viral concentrations of 30,000 vRNA per millilitre in the chronic phase. Owing to the high replicative capacity of SIVmac239, most drug-or vaccine-naive SIVmac239-infected monkeys die from AIDS-defining illnesses by 2 years after infection 11 . Three Mamu-B*08-restricted CD8
1 T-cell responses make up more than half of the T-cell response against the virus in Mamu-B*08 1 elite controllers 10, 12 ; these CD8 1 T cells recognize Vif RL8 (Vif amino acids 172-179), Vif RL9 (Vif amino acids 123-131) and Nef RL10 (Nef amino acids 137-146). CD8
1 T cells directed against these three epitopes select for escape mutations preferentially in Mamu-B*08 1 macaques that do not become elite controllers 13 , suggesting that these three immunodominant T-cell responses are important for the development of elite control.
To test the hypothesis that antigen-specific CD8 1 T cells are responsible for the development of elite control, we vaccinated eight Mamu-B*08 1 macaques (Fig. 1a , group 1) with two small regions of the SIV proteome that include the three immunodominant T-cell epitopes bound by Mamu-B*08: Vif RL8, Vif RL9 and Nef RL10. We used a recombinant yellow fever 17D (rYF17D) prime and boosted with recombinant adenovirus serotype 5 (rAd5). As controls, we vaccinated another eight Mamu-B*08 1 macaques (Fig. 1a , group 2) with two small regions of the SIV proteome that do not encode any known Mamu-B*08 epitopes 10 . The group 1 vaccinees mounted high frequency CD8
1 T-cell responses against the three Mamu-B*08-bound epitopes after vaccination, whereas the group 2 animals did not make CD8
1 T-cell responses against these three epitopes (Fig. 1b) . Group 1 and 2 animals exhibited similar SIV-specific total T-cell and CD4
1 T-cell response frequencies against the vaccine inserts after vaccination, as demonstrated by interferon (IFN)-c enzymelinked immunospot (ELISPOT) assay ( Supplementary Fig. 1a, b) .
Fifteen weeks after the final vaccine boost, we challenged all 16 animals intrarectally with a high dose of SIVmac239 (10,000 halfmaximal tissue-culture infectious dose (TCID 50 )). Four out of eight group 1 animals and six out of eight group 2 animals were infected after this first challenge. The remaining uninfected macaques were rechallenged with a second high dose of SIVmac239 (10,000 TCID 50 ) three weeks after the initial challenge. All of the group 2 controlvaccinated animals were infected after this second challenge. A single group 1 vaccinee, rh2355, resisted four high-dose SIVmac239 challenges and was only infected after the fifth challenge.
Surprisingly, all eight infected group 1 animals, vaccinated with the three immunodominant Mamu-B*08-restricted T-cell epitopes, controlled viral replication during acute infection when compared with the group 2 animals (Fig. 2a-d) . Remarkably, six of the seven group 1 vaccinated Mamu-B*08 1 animals that were infected after one or two challenges became elite controllers with post-acute phase viral loads of less than 1,000 vRNA copies per ml (Fig. 2a) . The seventh animal (rh2349) controlled viral replication to less than 10,000 vRNA copies per ml by 8 weeks after infection. The group 1 animal (rh2355) that required five high-dose challenges for infection controlled viral replication to less than 10,000 vRNA copies per ml by 10 weeks after infection. By contrast, viral replication in the group 2 animals was indistinguishable from viral replication in four concurrently challenged unvaccinated Mamu-B*08 1 controls (Fig. 2c) . We also measured viral replication during acute infection in lymph node biopsies using in situ hybridization 14, 15 . Group 1 animals demonstrated significantly less viral replication in lymph node tissue at time points near peak plasma viral load than group 2 animals (Fig. 2e) .
To evaluate potential correlates of viral protection in the group 1 vaccinees, we characterized the kinetics of T-cell responses after SIV infection using peptides and Mamu-B*08 tetramers. We first measured SIV-specific T-cell responses after infection in both group 1 and 2 vaccinated animals with a panel of synthetic peptides spanning 
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both the vaccine inserts and the entire SIV proteome using IFN-c ELISPOT ( Supplementary Fig. 1a, b) . Interestingly, peripheral blood mononuclear cell (PBMC) responses against the entire proteome were equivalent in the two groups after infection. At days 14 and 17 after infection, however, higher frequency insert-specific (total T cell and CD4 1 T-cell) and proteome-specific (CD4 1 T-cell) responses were observed in the group 1 animals, perhaps reflecting preservation of the CD4 1 T-cell responses owing to reduced peak viral replication in this group. These preserved antigen-specific CD4
1 T-cell responses may have facilitated the control of chronic phase viral replication in the group 1 animals. We also found that group 1 vaccinated macaques exhibited earlier and higher magnitude Vif RL9-and Nef RL10-specific responses in the peripheral blood than the group 2 macaques (Fig. 3a) . This pattern was also detected in lymph node biopsy specimens ( Fig. 3b ) and colon biopsy tissue (Fig. 3c) . Notably, T-cell responses directed against the Vif RL8 epitope were similar between the group 1 and 2 macaques (Fig. 3a-c) . Taken together, these results suggest that early, high frequency Vif RL9-and Nef RL10-specific responses in the blood and in key immunological tissues were directly responsible for viral control in the group 1 Mamu-B*08
1 macaques. Remarkably, we found a significant correlation between high frequency Nef RL10-specific responses and decreased day 14 peak viral loads ( Fig. 3d ) in our cohort of infected macaques. Furthermore, these vaccine-induced Nef RL10-specific CD8
1 T cells expressed both granzyme B and perforin at day 17 after infection, at a time when Nef RL10-specific CD8
1 T cells showed little or no expression of these important markers of cytotoxicity in the group 2 animals (Fig. 3e, f and Supplementary Fig. 2 ). Furthermore, the frequency of Nef RL10-(but not Vif RL8-or Vif RL9-) specific CD8
1 T-cell responses has recently been shown to correlate with the control of chronic phase viral replication in SIVmac239-infected, unvaccinated Mamu-B*08 1 macaques (D. Douek, personal communication). These results suggest that early, high frequency cytotoxic Nef RL10-specific responses in the blood and in key immunological tissues were directly responsible for viral control in group 1 Mamu-B*08 1 macaques. This is the first described correlate of viral control in the Mamu-B*08 model of elite control.
After controlling viral replication during the acute phase, increased plasma viraemia was observed in two of the group 1 vaccinees during the chronic phase (rh2349 and rh2355). Viral sequencing showed that despite the presence of wild-type virus in one of these two animals at 6 weeks after infection, all three targeted epitopes had escaped by the time viral replication started to increase in the chronic phase (Table 1 and Supplementary Fig. 3a, b) . By contrast, most of the three epitopes were intact in virus from two of the elite controllers in group 1 at 48 weeks after infection (Table 1 and Supplementary Fig. 3b ). This finding further implicates CD8
1 T cells against these three epitopes in control of viral replication, and suggests that the virus cannot replicate in the face of these CD8
1 T-cell responses. The canonical escape mutants that arose in these animals did not seem to affect viral fitness because the virus replicated to high levels in these two 'breakthrough' animals. Furthermore, we have previously engineered mutant viruses bearing several of the escape mutants observed in these animals and these mutations caused abrogation of CD8 1 T-cell recognition and did not seem to cause significant fitness loss in vitro and in vivo 10 .
With this report, we demonstrate that vaccine-induced Vif-and Nefspecific CD8
1 T cells can control replication of a highly pathogenic 
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AIDS virus in an animal model of MHC class I-associated elite control. Further analysis of the Vif RL9-and Nef RL10-specific CD8
1 T-cell responses in Mamu-B*08
1 macaques could shed light on the general principles of effective AIDS virus-specific CD8
1 T-cell responses. It is possible that vaccines that generate high frequency efficacious effector CD8
1 T cells against only a few epitopes in the mucosae might intercept the virus during this crucial acute phase and result in long-term virological control. These types of effective immune response might be inducible in the setting of an appropriate vaccination regimen [16] [17] [18] [19] . Therefore, understanding why these particular T-cell responses control viral replication when most other T-cell responses do not may enable the design of an effective approach to HIV vaccination. 
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METHODS SUMMARY
Animals. Animals were cared for according to Animal Welfare Assurance no. A3368-01 (protocol no. G00639). Vaccination. Animals were vaccinated subcutaneously with two separate rYF17D constructs (2.0 3 10 5 plaque-forming units of each) and were then boosted intramuscularly with two separate rAd5 vectors (10 11 particles of each) containing the same SIVmac239 inserts. SIV infection, in situ hybridization and viral load measurement. Animals were challenged intrarectally with 10,000 TCID 50 of SIVmac239. Viral loads were measured from EDTA anti-coagulated plasma using a previously described protocol 20 .
In situ hybridization of lymph node biopsy tissues was performed as previously described 14, 15 . Tetramer staining and flow cytometry. For tetramer staining, we followed previously published staining protocols 10 . Amplicon-based 454 sequencing of Vif and Nef epitopes in plasma virus. We used an amplicon-based 454 sequencing approach to analyse the Vif and Nef epitopes as previously described 13 . A single-step reverse transcription PCR (RT-PCR) was carried out for each of the unique amplicon/animal/multiplex-identifier-tag sequence combinations using SuperScript III one-step RT-PCR system. Sequencing and run processing were performed on a GS Junior 454 sequencing instrument. We used the ReadClean 454 (RC454) and V-Phaser algorithms as previously described 21, 22 to call variants from the 454 data sets. Statistics. We compared the geometric mean of viral loads and the mean of SIV-RNA 1 cells per mm 2 for each time point and then performed Mann-Whitney tests. We also used the Mann-Whitney test to compare the magnitude of SIVspecific T-cell responses in groups 1 and 2. We determined correlation coefficients (r) and P values using the Spearman rank correlation test. All significance tests were two-tailed.
Author Information The sequence data for this study are available at the NCBI Sequence Read Archive (http://www.ncbi.nlm.nih.gov/Traces/sra) under accession number SRA055739. Reprints and permissions information is available at www.nature.com/reprints. The authors declare competing financial interests: details are available in the online version of the paper. Readers are welcome to comment on the online version of the paper. Correspondence and requests for materials should be addressed to D.I.W. (dwatkins@med.miami.edu). Fig. 2c were also raised in-house at the WNPRC. All animals were housed and studies were conducted at the WNPRC. Animals were cared for according to the regulations and guidelines of the University of Wisconsin Institutional Animal Care and Use Committee, Animal Welfare Assurance no. A3368-01. Full details of the study were approved (University of Wisconsin-Madison Animal Care and Use Protocol no. G00639) by the University of Wisconsin Institutional Animal Care and Use Committee in accordance with the recommendations of the Weatherall report. Macaques in groups 1 and 2 (n 5 16) were males, with a mean age of 7.95 years (range 7.1-9.2). The four unvaccinated, Mamu-B*08
1 control animals were also males and their mean age was 12.4 years (range 7.5-18.3). Among the eight unvaccinated, Mamu-B*08 2 control animals, six were males and two were females; their mean age was 8.3 years (range 7.7-9.2). Once infected, animals were singly housed to prevent cross contamination of SIV infection and spread of opportunistic infections. Animals were closely monitored daily for pain or discomfort and treated accordingly by a veterinarian to ameliorate any suffering. After progression to AIDS or at the end of the study, animals with high viral loads were humanely euthanized. Animals that controlled viral replication during this study have been maintained for continuing study as a part of the elite controller resource at the Wisconsin National Primate Research Center. Group 1 vaccinee rh2349 was euthanized at 35 weeks after infection after a 20% loss of its body weight. At necropsy, this animal had right-sided dilated cardiomyopathy and cardiomyocyte necrosis, with minimal inflammation. This may be related to SIV infection but it is not a typical lesion. All animals were MHC class I-typed to verify the presence of the Mamu-B*08 allele according to a previously reported protocol 9 . Fig. 1a . Animals receiving the three immunodominant Mamu-B*08-restricted epitopes were vaccinated with two separate rYF17D constructs. rYF17D viruses were created with a single insert between the viral proteins E and NS1, as previously described 23, 24 . The first was engineered to contain SIVmac239 Vif amino acids 102-214 (including the Vif 123-131 RL9 and Vif 172-179 RL8 epitopes), and the second contained SIVmac239 Nef amino acids 45-210 (including the Nef 137-146 RL10 epitope). Animals were vaccinated subcutaneously with 2.0 3 10 5 plaque-forming units of each of these constructs in separate locations on each forearm. The animals were then boosted intramuscularly in each thigh 4 weeks later with two separate doses of 10 11 particles of rAd5 vectors (Viraquest) each containing SIVmac239 Vif and Nef inserts identical to those in the rYF17D. Control vaccinated animals underwent the same vaccination regimen, except rYF17D and recombinant adenoviral vectors included portions of SIVmac239 without known Mamu-B*08 epitopes 10 -SIVmac239 Vif amino acids 1-110 and SIVmac239 Gag amino acids 178-258. SIV infection and viral load measurement. Animals in groups 1, 2 and the unvaccinated Mamu-B*08 1 controls were challenged intrarectally with 10,000 TCID 50 (8.15 3 10 7 vRNA copies) of SIVmac239 15 weeks after vaccination with rAd5. Animals that remained uninfected after the initial inoculation were challenged a second time 3 weeks later. The group 1 vaccinee rh2355 resisted a total of four challenges. Each of these intrarectal inoculations occurred approximately 3 weeks after the previous challenge. The eight unvaccinated, Mamu-B*08 -animals described in Fig. 2c were used as experimental controls as part of a separate SIV vaccine trial conducted in our laboratory (M.A.M. et al., manuscript in preparation). They were challenged intrarectally every week with the same stock of SIVmac239 described above, albeit at doses ranging from 800 to 50,000 TCID 50 (6.52 3 10 6 to 4.07 3 10 8 vRNA copies, respectively). Clonal SIVmac239 was generated by transfection of Vero cells with plasmid DNA encoding proviral sequences. Activated PBMCs from four SIV-naive rhesus macaques were then added to the culture 1 day later and removed from the Vero cells into flasks 3 days after the initial transfection. Virus was amplified in the activated PBMCs and cell-free supernatant was collected 2 days after peak syncytium formation. Viral loads were measured from EDTA anti-coagulated plasma following a previously described protocol 20 . Viral RNA was dissolved in 30 ml 10 mM TrisCl, pH 8.0. Samples were run in duplicate. Each reaction contained 10 ml RNA and 20 ml of a reverse transcriptase master mix so that the final reactions contained 50 mM Tris-HCl, pH 8. 
Vaccination. Vaccinated animals received constructs as shown in
was removed from the thermocycler. At the second 25 uC stage, or later, the reactions were unsealed and 20 ml of a cocktail containing primers, probe and thermostable polymerase were added so that the final reactions contained 13 PCR II buffer, 0.03% gelatin, 0.012% Tween 20, 4.5 mM MgCl 2 , 600 nM of each primer (forward primer (SGAG21), 59-GTCTGCGTCATPTGGTGCATTC-39, reverse primer (SGAG22), 59-CACTAGKTGTCTCTGCACTATPTGTTTTG-39), 100 nM probe (pSGAG23, 59-(FAM)CTTCPTCAGTKTGTTTCACTTTCTCT TCTGCG-(BHQ)-39), 45 nM SuperROX passive reference dye (Biosearch Technologies), and 1.25 U Taq-gold polymerase (Life Technologies). P and K are nonstandard bases (Glen Research) that minimize the effect of potential sequence mismatches at positions of described heterogeneity in SIV isolates (Los Alamos Sequence Database); FAM is the reporter fluorochrome 6-carboxyfluoroscein; BHQ is black hole quencher (Biosearch Technologies); and ROX is 5-carboxyrhodamine. The final reactions were then run on an ABI 7500 Sequence Detection System (Life Technologies). The run conditions were 95 uC for 10 min, followed by 45 cycles of 95 uC for 15 s and 60 uC for 1 min. Copy numbers for test samples were determined using an RNA standard curve run at the same time. Thirty viral copy equivalents per milliltire of plasma is the limit of reliable quantification for this assay. Colon and lymph node biopsies. Lymph node and colon biopsies were obtained from all animals with positive viral loads on days 9, 14 and 21 after SIVmac239 infection. Animals were anaesthetized and a single inguinal or axillary lymph node was obtained from a separate biopsy site each day by a veterinarian using aseptic technique. Lymph node biopsy specimens were sieved through a 100-mm screen to obtain a single-cell suspension and any remaining red blood cells were removed by hypotonic lysis. During the same anaesthetic event, colon biopsy samples (approximately ten separate 2 3 2 3 2 mm pieces of tissue) were collected by the veterinarian using a pinch biopsy device and a fibre optic endoscope. Colon biopsy samples were washed with R10 (RPMI 1640 media supplemented with 10% FBS, 1% antibiotic/antimycotic and 1% L-glutamine) and then resuspended in predigestion buffer (HBSS supplemented with 5% FBS, 1% antibiotic/antimycotic, 5 mM EDTA and 1 mM DTT), and incubated in an orbital shaker at 50 r.p.m., 37 uC for 30 min. Samples were then washed once with R10 media and resuspended in collagenase medium (R10 with 15 mg ml 21 type II collagenase from Clostridium histolyticum (Sigma-Aldrich)) and incubated at 50 r.p.m., 37 uC for 30 min. The supernatant was collected and lamina propria lymphocytes (LPL) contained within the supernatant were washed three times with R10 media. The collagenase digestion was repeated twice more and the collected, washed LPL were pooled in R10 media and layered over a 40-90% Percoll gradient before being centrifuged for 30 min at 450g. Purified LPL were collected from the interface between the 40% and 90% Percoll layers and washed once with R10 media before being counted and stained for flow cytometry. In situ hybridization. In situ hybridization was performed as previously described 14, 15 . In brief, 5-mm sections were cut from 4% paraformaldehyde-fixed lymph node tissues. After deparaffinization, pretreatment to permeabilize the tissues and blocking of non-specific binding, the sections were hybridized to 35 S-labelled SIV RNA antisense or sense (as a negative control) riboprobes covering SIV sequences at the 59, middle and 39 end of the genome. After overnight hybridization at 45 uC, the sections were washed, digested with RNases, coated with nuclear track emulsion, exposed, developed and counterstained with haematoxylin and eosin. Viral load was quantified as SIV RNA 1 cells per mm 2 of tissue. Tetramer staining and flow cytometry. For tetramer staining, we used MHC class I tetramers produced by the Wisconsin National Primate Research Center Tetramer Core conjugated to either phycoerythrin or allophycocyanin. Prepared PBMCs, lymph node cells or colon biopsy cells suspended in R10 were centrifuged for 5 min at 530g in 1.2-ml cluster tubes and excess media was aspirated leaving all samples in 100-200 ml of R10. Approximately 50,000-100,000 colon biopsy cells or 500,000-1,000,000 PBMC/lymph node cells were stained with tetramer for 90 min at 37 uC. After the incubation, surface staining antibodies were added and samples were incubated at room temperature for 30 min. Cells were then washed twice with FACS buffer (PBS with 10% FBS) and fixed with 1% paraformaldehyde in PBS. Cells were run on a BD-LSRII instrument (BD Biosciences) and analysis was performed using FlowJo software (version 9.3.1, Tree Star). We used the following antibodies from BD Biosciences during this study: anti-CD3 Alexa Fluor 700 (clone SP34-2) and anti-CD8 pacific blue (RPA-T8).
For the MHC class I tetramer/granzyme B combined staining, cryopreserved PBMCs were thawed at 37 uC and washed twice in R10 media before staining. Approximately 2.0 3 10 5 -2.0 3 10 6 PBMCs were stained with 5 ml of phycoerythrin-conjugated tetramer in a volume of 100-200 ml of R10 media for 90 min at 37 uC. Cells were then stained with 2 ml anti-CD3 Alexa Fluor 700 (clone SP34-2; BD Biosciences) and 1 ml anti-CD8 Pacific Blue (clone RPA-T8; BD Biosciences) for 30 min at room temperature. Subsequent washes and fixation
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with 1% paraformaldehyde were performed as described above. Fixed cells were washed twice with FACS buffer, and excess liquid was aspirated to leave samples in approximately 75 ml of FACS buffer. Cells were then permeabilized by adding 100 ml medium B (Life Technologies), and simultaneously stained for granzyme B with 1 ml anti-GzmB allophycocyanin (clone GB12; Life Technologies) for 30 min at room temperature. Cells were then washed twice with FACS buffer, and fixed in 1% paraformaldehyde. Cells were run on a SORP BD-LSRII (BD Biosciences) and analysis was performed using FlowJo software (version 9.4.2, Tree Star). Owing to sample limitations, only rh2350, rh2352, rh2361 and rh2365 from group 1 and rh2351, rh2353, rh2354 and rh2360 from group 2 were included in this analysis. IFN-c and perforin ELISPOT. ELISPOT assays were performed on PBMCs or PBMCs depleted of CD8 1 cells at the indicated time points. CD8 depletion was performed on PBMCs before ELISPOT in some assays using the Miltenyi Biotec non-human primate CD8 MicroBead kit and LS columns according to the manufacturer's protocols (Miltenyi Biotec). CD8 depletion was determined to be .99% in every assay performed. All IFN-c and perforin ELISPOT assays (ELISpot PLUS -ALP) were performed with 100,000 cells per well, in duplicate, according to the manufacturer's instructions (MABTECH). For all IFN-c assays, we used pools of peptides (ten peptides of 15 residues each, each overlapping by 11 amino acids) covering the SIVmac239 antigens, and these pools were tested at a final concentration of 1 mM. For the perforin assays, only the minimal peptides were tested, each at a final concentration of 10 mM. Each individual animal on each separate plate included at least two separate positive control wells (5 mg ml 21 concanavalin A) and two or more negative control wells. Wells were imaged and spots were enumerated with an AID ELISPOT reader (AID). Positive responses were determined as follows: test wells were run with two replicates whereas positive and negative control wells were run in replicates of 2, 4 or 6 depending on the assay. Responses containing ,50 spot-forming cells (SFC) per 10 6 cells were considered negative and not tested statistically. Positive responses were determined using a one-tailed t-test and a 5 0.05, in which the null hypothesis (H 0 ): background level 5 treatment level. If determined to be positive statistically, the reported values equal the average of the test wells minus the average of all negative control wells. For the perforin ELISPOT in Fig. 3f , we only included rh2350, rh2352, rh2361 and rh2365 from group 1 and rh2351, rh2353, rh2354 and rh2360 from group 2 in the analysis owing to sample limitations. Amplicon-based 454 sequencing of Vif and Nef epitopes. One to three millilitres of plasma was thawed on ice and centrifuged at 20,817g for 1.5 h at 4 uC, after which the pellet was resuspended in 140 ml of the supernatant. The QIAamp viral RNA mini kit (Qiagen) was used to isolate viral RNA per manufacturer protocol. Viral RNA was eluted in 60 ml of buffer AVE, aliquoted and stored at 280 uC for future RT-PCR.
An amplicon-based 454 sequencing approach was used to analyse the Vif and Nef epitopes as previously described 13 . In brief, primers were synthesized with Roche 454 amplicon (Lib-A) adaptor sequences, multiplex identifier tags (MID) 1 to 18, and sequence-specific regions (Vif: forward, 59-GAAAAAGGGTGGCTCA GT-39, reverse, 59-AGGTGGTTTACCGCCTCTCT-39; Nef: forward, 59-ACT GGAAGGGATTTATTAC-39, reverse, 59-GAGTTTCCTTCTTGTCAGCC-39), which allowed multiplexing of up to 16 animal/amplicon combinations per sequencing run.
A single-step RT-PCR was carried out for each of the unique amplicon/animal/ MID sequence combinations using SuperScript III one-step RT-PCR system with platinum Taq high fidelity (Invitrogen). Each 25-ml reaction contained 12.5 ml of 23 reaction mix, a further 0.3 mM MgSO 4 , 1 ml of enzyme mix, 0.2 mM each of the sequence specific, adaptor/MID-tagged forward and reverse primers, and up to 10 ml of template RNA. Cycling parameters for the Vif RT-PCR were as follows: 50 uC for 30 min, 94 uC for 2 min followed by 40 cycles of 94 uC for 15 s, 50 uC for 30 s and 68 uC for 30 s, 68 uC for 5 min, hold at 10 uC. The Nef RT-PCR parameters were identical with the exception of an annealing temperature of 54 uC. Amplicons were visualized on a 1% agarose gel and purified using the Purelink quick gel extraction kit (Invitrogen). RT-PCR products were quantified using a Promega quantiflor-ST fluorometer (Promega) and analysed for quality using an Agilent 2100 bioanalyzer with high sensitivity DNA chips.
For each sequencing run, up to 16 animal/amplicon samples were pooled in equimolar ratios and 20 million molecules of pooled sample were added to 10 million DNA capture beads for a final ratio of 2.0 DNA molecules per bead. Emulsion PCR, enrichment, breaking and DNA sequencing were all performed according to the GS Junior FLX titanium series manuals for Lib-A (Roche). Sequencing and run processing were performed on a GS Junior 454 sequencing instrument (Roche).
We used the ReadClean 454 (RC454) and V-Phaser algorithms as previously described 21 to call variants from the 454 data sets. In brief, RC454 was used to align reads to SIVmac239 and reads were corrected for sequencing related artefacts such as indels resulting from overcalls and undercalls in homopolymeric regions and carry forward and incomplete extension (CAFIE) errors. Furthermore, RC454 optimizes read alignments using coding-frame information. The V-Phaser algorithm was then used to distinguish an observed variant as a true variant from an amplification or sequencing artefact LETTER RESEARCH
